Jean Yves Reginster

Summary

Country: Belgium

Publications

  1. ncbi Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, Centre Hospitalier Universitaire Centre Ville, B 4020 Liege, Belgium
    J Clin Endocrinol Metab 90:5018-24. 2005
  2. ncbi Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
    Jean Yves Reginster
    Correspondence to Professor Jean Yves Reginster, Department of Public Health and Health Economics, University of Liege, 4020 Liege, Belgium
    Ann Rheum Dis 72:179-86. 2013
  3. ncbi Role of glucosamine in the treatment for osteoarthritis
    Jean Yves Reginster
    Department of Public Health Sciences, CHU Sart Tilman, University of Liege, Liege, Belgium
    Rheumatol Int 32:2959-67. 2012
  4. ncbi Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 23:S1-23. 2012
  5. ncbi Alcohol and bone: review of dose effects and mechanisms
    D B Maurel
    Unité Inserm U658, Caracterisation du Tissu Osseux par Imagerie, techniques et applications, CHR Orleans, 45000 Orléans, France
    Osteoporos Int 23:1-16. 2012
  6. ncbi Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
    J Y Reginster
    Department of Public Health and Health Economics, University of Liege, Liege, Belgium
    Osteoporos Int 23:1115-22. 2012
  7. ncbi Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club
    J J Body
    Internal Medicine, Institut Jules Bordet, Brussels, Belgium
    Osteoporos Int 22:2769-88. 2011
  8. ncbi Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 21:1657-80. 2010
  9. ncbi Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis
    Rene Rizzoli
    Division of Bone Disease, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
    Calcif Tissue Int 89:91-104. 2011
  10. ncbi Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
    BMC Musculoskelet Disord 9:32. 2008

Detail Information

Publications126 found, 100 shown here

  1. ncbi Monthly oral ibandronate is well tolerated and efficacious in postmenopausal women: results from the monthly oral pilot study
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, Centre Hospitalier Universitaire Centre Ville, B 4020 Liege, Belgium
    J Clin Endocrinol Metab 90:5018-24. 2005
    ....
  2. ncbi Efficacy and safety of strontium ranelate in the treatment of knee osteoarthritis: results of a double-blind, randomised placebo-controlled trial
    Jean Yves Reginster
    Correspondence to Professor Jean Yves Reginster, Department of Public Health and Health Economics, University of Liege, 4020 Liege, Belgium
    Ann Rheum Dis 72:179-86. 2013
    ..The international, double-blind, randomised, placebo-controlled Strontium ranelate Efficacy in Knee OsteoarthrItis triAl evaluated its effect on radiological progression of knee osteoarthritis...
  3. ncbi Role of glucosamine in the treatment for osteoarthritis
    Jean Yves Reginster
    Department of Public Health Sciences, CHU Sart Tilman, University of Liege, Liege, Belgium
    Rheumatol Int 32:2959-67. 2012
    ....
  4. ncbi Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 23:S1-23. 2012
    ..Drugs used for the prevention and the treatment of osteoporosis exert various favourable and unfavourable extra-skeletal effects whose importance is increasingly recognized notably for treatment selection...
  5. ncbi Alcohol and bone: review of dose effects and mechanisms
    D B Maurel
    Unité Inserm U658, Caracterisation du Tissu Osseux par Imagerie, techniques et applications, CHR Orleans, 45000 Orléans, France
    Osteoporos Int 23:1-16. 2012
    ..The roles of reduced total fat mass, increased lipid content in bone marrow, and a hypoleptinemia are also discussed...
  6. ncbi Maintenance of antifracture efficacy over 10 years with strontium ranelate in postmenopausal osteoporosis
    J Y Reginster
    Department of Public Health and Health Economics, University of Liege, Liege, Belgium
    Osteoporos Int 23:1115-22. 2012
    ..01). Vertebral and nonvertebral fracture incidence was lower between 5 and 10 years than in a matched placebo group over 5 years (P < 0.05). Strontium ranelate's antifracture efficacy appears to be maintained long term...
  7. ncbi Non-pharmacological management of osteoporosis: a consensus of the Belgian Bone Club
    J J Body
    Internal Medicine, Institut Jules Bordet, Brussels, Belgium
    Osteoporos Int 22:2769-88. 2011
    ..Several randomized controlled studies had reported a short-term advantage of vertebroplasty over medical treatment for pain relief, but these findings have been questioned by recent sham-controlled randomized clinical studies...
  8. ncbi Evidence-based guidelines for the pharmacological treatment of postmenopausal osteoporosis: a consensus document by the Belgian Bone Club
    J J Body
    Department of Medicine, CHU Brugmann, Universite Libre de Bruxelles, Brussels, Belgium
    Osteoporos Int 21:1657-80. 2010
    ..It offers an evidence-based update of previous treatment guidelines, with the aim of providing clinicians with an unbiased assessment of osteoporosis treatment effect...
  9. ncbi Adverse reactions and drug-drug interactions in the management of women with postmenopausal osteoporosis
    Rene Rizzoli
    Division of Bone Disease, Department of Rehabilitation and Geriatrics, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland
    Calcif Tissue Int 89:91-104. 2011
    ..While these are a cause for concern, the risk should be weighed against the benefits of treatment itself, i.e., the prevention of osteoporotic fracture...
  10. ncbi Long-term retention on treatment with lumiracoxib 100 mg once or twice daily compared with celecoxib 200 mg once daily: a randomised controlled trial in patients with osteoarthritis
    Roy Fleischmann
    The University of Texas Southwestern Medical Center at Dallas, MCRC, Dallas, Texas, USA
    BMC Musculoskelet Disord 9:32. 2008
    ..d.) and 100 mg twice daily (b.i.d.) with those of celecoxib 200 mg o.d. on retention on treatment over 1 year...
  11. ncbi Raloxifene reduces fractures in postmenopausal women with osteoporosis
    Jean Yves Reginster
    Department of Public Health, Epidemiology and Health Economics, University of Liège and the World Health Organization Collaborating Centre for Public Health Aspects of Bone Diseases, Liege, Belgium
    Clin Orthop Relat Res 443:48-54. 2006
    ..See the Guidelines for Authors for a complete description of the levels of evidence...
  12. ncbi Strontium ranelate: the first dual acting treatment for postmenopausal osteoporosis
    Nansa Burlet
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liege, Belgium
    Clin Orthop Relat Res 443:55-60. 2006
    ..See the Guidelines for Authors for a complete description of the levels of evidence...
  13. ncbi Osteoporosis: a still increasing prevalence
    Jean Yves Reginster
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, and Bone and Cartilage Research Unit, CHU Centre Ville, Policliniques L Brull, Quai Godefroid Kurth 45 9th floor, University of Liege, 4020 Liege, Belgium
    Bone 38:S4-9. 2006
    ..Programs to increase awareness of osteoporosis and its outcomes are necessary for healthcare specialists and the general public. Earlier diagnosis and intervention prior to the first fracture are highly desirable...
  14. ncbi Adherence and persistence: impact on outcomes and health care resources
    Jean Yves Reginster
    World Health Organisation Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liege, 4020 Liege, Belgium
    Bone 38:S18-21. 2006
    ..Use of biochemical markers of response or BMD measurements to illustrate response to patients may be useful in this regard. Simplification of treatment regimens would also be of considerable value in improving adherence and persistence...
  15. ncbi Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study
    J Y Reginster
    University of Liege, Liege, Belgium
    Ann Rheum Dis 65:654-61. 2006
    ..Reducing bisphosphonate dosing frequency may improve suboptimal adherence to treatment and therefore therapeutic outcomes in postmenopausal osteoporosis. Once-monthly oral ibandronate has been developed to overcome this problem...
  16. ncbi Oral and intravenous ibandronate in the management of postmenopausal osteoporosis: a comprehensive review
    J Y Reginster
    WHO Collaborating Centre for Public Health Aspects of Rheumatic Diseases, Liege, Belgium, Bone and Cartilage Metabolism Unit, University of Liege, Belgium
    Curr Pharm Des 11:3711-28. 2005
    ..These simple ibandronate regimens are expected to provide the optimal combination of efficacy, tolerability and patient convenience, leading to improved treatment adherence and thus, enhanced outcomes in postmenopausal osteoporosis...
  17. ncbi [Adherence to treatment in osteoporosis influence on efficiency]
    J Y Reginster
    Unité d exploration du métabolisme de l os et du cartilage CHU Centre Ville 45, Quai Godefroid Kurth 4020 Liège, Belgique
    Rev Med Suisse 1:2278-81. 2005
    ..New medications, currently developed for the management of osteoporosis, will be user-friendly, allowing to an improvement of compliance and persistence...
  18. ncbi Oral ibandronate: a less frequently administered therapeutic option for postmenopausal osteoporosis
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, CHU Centre Ville, Liege, Belgium
    Expert Opin Pharmacother 6:2301-13. 2005
    ..This article reviews the pharmacology, efficacy and tolerability of oral ibandronate when administered with extended dosing intervals in postmenopausal osteoporosis...
  19. ncbi Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, Liege, Belgium
    J Rheumatol Suppl 76:21-5. 2005
    ..Compared to plain vitamin D, alfacalcidol exerts higher bone-protective effects, thus allowing the doses to be minimized and lowering the risk of adverse effects, including hypercalcemia...
  20. ncbi Strontium ranelate: a new treatment for postmenopausal osteoporosis with a dual mode of action
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques L Brull, Quai Godefroid Kurth 45 9ème étage, 4020 Liege, Belgium
    Curr Osteoporos Rep 3:30-4. 2005
    ....
  21. ncbi A new concept for bisphosphonate therapy: a rationale for the development of monthly oral dosing of ibandronate
    Jean Yves Reginster
    Unite d Exploration du Metabolisme de l Os et du Cartilage, CHU Centre Ville, Liege, Belgium
    Osteoporos Int 17:159-66. 2006
    ..Greater convenience and tolerability may enhance the therapy adherence and, hence, improve long-term therapeutic outcomes in PMO...
  22. ncbi Intermittent bisphosphonate therapy in postmenopausal osteoporosis: progress to date
    Jean Yves Reginster
    Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, University of Liege, Liege, Belgium
    Drugs Aging 24:351-9. 2007
    ....
  23. ncbi Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study
    J Y Reginster
    Department of Epidemiology, Public Health and Health Economics, University of Liege, CHU Centre Ville, 45 Quai Godefroid Kurth, 4020 Liege, Belgium
    J Clin Endocrinol Metab 90:2816-22. 2005
    ....
  24. ncbi [Treatment of postmenopausal osteoporosis in 2004]
    J Y Reginster
    Centre Collaborateur de l Institut Mondial de la Santé pour les Aspects de Santé Publique des Maladies Rhumatismales, Liege, Belgique
    Rev Med Liege 59:633-47. 2004
    ..Strontium ranelate offers an anti-fracture efficacy at all skeleton sites and an oustanding overall tolerance and may play a main role in the future management of osteoporosis...
  25. ncbi Adherence, patient preference and dosing frequency: understanding the relationship
    J Y Reginster
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liege, Liege, Belgium
    Bone 38:S2-6. 2006
    ..A novel once-monthly bisphosphonate regimen, such as the ibandronate regimen, may therefore help patients to follow dosing guidelines and encourage them to stay on therapy longer, thereby improving overall therapy effectiveness...
  26. ncbi [Glucosamine as a pain-modifying drug in osteorthritis. What's new in 2006]
    J Y Reginster
    Service de Sante Publique, épidémiologie et économie de la santé
    Rev Med Liege 61:169-72. 2006
    ..Their results are supported by new pharmacokinetic and preclinical studies, explaining the mode of action of glucosamine in osteoarthritis...
  27. ncbi Strontium ranelate: a look back at its use for osteoporosis
    Jean Yves Reginster
    University of Liege, Department of Public Health Sciences, Liege, Belgium
    Expert Opin Pharmacother 11:2915-27. 2010
    ..Osteoporosis is now considered a major health problem in all developed and in most developing (non-African) countries...
  28. ncbi Ibandronate in profile: drug characteristics and clinical efficacy
    Jean Yves Reginster
    University of Liege, Public Health and Health Economics, Liege, Belgium
    Expert Opin Drug Metab Toxicol 4:941-51. 2008
    ..Postmenopausal osteoporosis is a serious, chronic condition, for which nitrogen-containing bisphosphonates are now one of the treatments of choice...
  29. ncbi Injectable bisphosphonates for the treatment of osteoporosis
    Jean Yves Reginster
    University of Liege, Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques L Brull, Quai Godefroid Kurth 45 9ème étage, 4020 Liege, Belgium
    Womens Health (Lond Engl) 3:719-23. 2007
    ..Intravenous administration of bisphosphonates can now be considered as an important component of the management of postmenopausal osteoporosis...
  30. ncbi Strontium ranelate: new data on fracture prevention and mechanisms of action
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques L Brull, 4020 Liege, Belgium
    Curr Osteoporos Rep 7:96-102. 2009
    ..Due to a positive risk/benefit ratio, strontium ranelate is now considered as a first-line treatment in the management of osteoporosis...
  31. ncbi Long-term treatment of postmenopausal osteoporosis with strontium ranelate: results at 8 years
    J Y Reginster
    Department of Public Health Sciences, University of Liege, Liege, Belgium
    Bone 45:1059-64. 2009
    ..This article describes the efficacy, safety, and tolerability of this agent over 8 years...
  32. ncbi [Strontium ranlelate (Protelos)]
    J Y Reginster
    Service de Sante Publique, épidémiologie et économie de la santé, ULg, CHU Sart Tilman, Liege
    Rev Med Liege 62:685-7. 2007
    ..It is currently reimbursed, in Belgium, in osteoporotic patients aged 80 years and older. In this group, it is the only drug which has shown an extensive range of anti-fracture efficacy...
  33. ncbi Patient preference in the management of postmenopausal osteoporosis with bisphosphonates
    Jean Yves Reginster
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, University of Liege, Liege, Belgium
    Clin Interv Aging 1:415-23. 2006
    ..It is important that physicians consider patient preference when prescribing treatment for osteoporosis to ensure that the disease is effectively managed for the long-term benefit of the patient...
  34. ncbi Symptom and structure modifying properties of chondroitin sulfate in osteoarthritis
    Jean Yves Reginster
    Department of Public Health Economics, University of Liege, Liege, Belgium
    Mini Rev Med Chem 7:1051-61. 2007
    ..CS exhibits a wide range of biological activities. Many experimental and clinical data are available, affirming that CS represents an effective and safe symptomatic treatment of osteoarthritis (OA) with delayed and sustained effects...
  35. ncbi [Advances in the treatment of postmenopausal osteoporosis]
    J Y Reginster
    Service de Sante Publique, épidémiologie et économie de la santé, ULg, CHU Sart Tilman, Liege
    Rev Med Liege 62:352-9. 2007
    ..Currently, it is the only drug which has shown an extensive anti-fracture efficacy in elderly subjects over 80 years old...
  36. ncbi Calcium and vitamin D for osteoporotic fracture risk
    Jean-Yves Reginster
    Bone and Cartilage Metabolism Unit, CHU Centre Ville, 4020 Liege, Belgium
    Lancet 370:632-4. 2007
  37. ncbi Current role of glucosamine in the treatment of osteoarthritis
    J Y Reginster
    WHO Collaborating Center, Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
    Rheumatology (Oxford) 46:731-5. 2007
    ..To evaluate the interest of using the various preparations of glucosamine for symptomatic and structural management of osteoarthritis (OA)...
  38. ncbi Strontium ranelate in the prevention of osteoporotic fractures
    J Y Reginster
    Bone and Cartilage Metabolism Unit, University of Liege, Liege, Belgium
    Int J Clin Pract 61:324-8. 2007
    ..A preplanned analysis of a sub-group of patients aged 80 years and over showed that, currently, strontium ranelate is the only antiosteoporotic agent to reduce vertebral and non-vertebral fractures in this age group...
  39. ncbi [Ibandronate (Bonviva) in the treatment of postmenopausal osteoporosis]
    J Y Reginster
    Service de Sante Publique, Epidemiologie, Economie de la Santé, CHU Sart Tilman, Liege, Belgique
    Rev Med Liege 61:783-6. 2006
    ..This monthly formulation has a safety profile similar to the one observed with the daily administration of the compound. Adherence to monthly bisphosphonates appears to be significantly higher than for daily or weekly administration...
  40. ncbi Clinical utility of a pharmacostatistical model for ibandronate in postmenopausal osteoporosis
    J Y Reginster
    WHO Collaborating Centre for Public Health Aspects of Rheumatic Diseases, Liege, Belgium
    Curr Drug Metab 7:827-36. 2006
    ....
  41. ncbi Antifracture efficacy of currently available therapies for postmenopausal osteoporosis
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Liege, Belgium
    Drugs 71:65-78. 2011
    ....
  42. ncbi [Chondromodulation in 2003: dream or reality?]
    Jean Yves Reginster
    Service de Sante Publique, d épidémiologie et économie de la santé, CHU Sart Tilman Bâtiment B23 B 4000 Liège
    Rev Med Suisse Romande 124:85-7. 2004
    ..Encouraging results have also been obtained with chondroitin sulfate and diacerein. As for other molecules, new studies should be undertaken to confirm the results already obtained...
  43. ncbi Strontium ranelate: a new paradigm in the treatment of osteoporosis
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques Lucien Brull, Quai Godefroid Kurth 45 9ème étage, 4020 Liege, Belgium
    Expert Opin Investig Drugs 13:857-64. 2004
    ..A reduction in the risk of experiencing a hip fracture was also demonstrated in the patients treated for > or = 18 months...
  44. ncbi Strontium ranelate in osteoporosis
    J Y Reginster
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liege, Belgium
    Curr Pharm Des 8:1907-16. 2002
    ..The primary analysis of the SOTI study, evaluating the effect of 2 g of strontium ranelate on vertebral fracture rates are expected to be released during the summer 2002...
  45. ncbi Strontium ranelate: a new paradigm in the treatment of osteoporosis
    J Y Reginster
    WHO Collaborating Center for Public Health Aspects of Rheumatic Diseases, Liege, Belgium
    Drugs Today (Barc) 39:89-101. 2003
    ..All these results imply that strontium ranelate is a new, effective and safe treatment for vertebral and nonvertebral osteoporosis, with a unique mode of action...
  46. ncbi Reduction in PINP, a marker of bone metabolism, with raloxifene treatment and its relationship with vertebral fracture risk
    J Y Reginster
    CHU Centre Ville, Liege, Belgium
    Bone 34:344-51. 2004
    ..In conclusion, a 1-year decrease in PINP, BSAP, or OC, but not CTx/Cr, may be predictive of the 3-year VF risk reduction with raloxifene therapy in this subset of postmenopausal women with osteoporosis...
  47. ncbi Strontium ranelate phase 2 dose-ranging studies: PREVOS and STRATOS studies
    J Y Reginster
    Bone and Cartilage Metabolism Unit, CHU Centre Ville, Quai Godefroid Kurth 45 9, 4020, Liege, Belgium
    Osteoporos Int 14:S56-65. 2003
    ..The minimum dose at which SR is effective in preventing bone loss in early postmenopausal nonosteoporotic women and in the treatment of postmenopausal osteoporosis is 1 g/day and 2 g/day, respectively...
  48. ncbi Effect of raloxifene combined with monofluorophosphate as compared with monofluorophosphate alone in postmenopausal women with low bone mass: a randomized, controlled trial
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, Liege, Belgium
    Osteoporos Int 14:741-9. 2003
    ....
  49. ncbi [Prevention of hip fractures in the elderly: where are we in 2003?]
    J Y Reginster
    Service de Sante Publique, épidémiologie et économie de la santé, Univ de Liège, l Institut Mondial de la Santé pour les Aspects de Santé Publique des Maladies Rhumatismales, Liege
    Rev Med Liege 58:183-90. 2003
    ..The present article reviews the current evidence available to justify anti-osteoporotic medications to be recommended to very elderly subjects, in the perspective of reducing their risk of appendicular fractures...
  50. ncbi Naturocetic (glucosamine and chondroitin sulfate) compounds as structure-modifying drugs in the treatment of osteoarthritis
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, Belgium
    Curr Opin Rheumatol 15:651-5. 2003
    ..Several entities have been investigated carefully for the symptomatic and structural management of osteoarthritis. This review reports recent findings suggesting that such compounds may delay the structural progression of osteoarthritis...
  51. ncbi New perspectives in the management of osteoarthritis. structure modification: facts or fantasy?
    Jean Yves Reginster
    Bone and Cartilage Metabolism Research Unit, University of Liege, CHU Centre Ville, Policliniques L Brull, Liege, Belgium
    J Rheumatol Suppl 67:14-20. 2003
    ..An important issue is that all conclusive studies with such chemical entities resulted from the use of prescription medicines and not over-the-counter or nutriceutical supplements...
  52. ncbi Influence of daily regimen calcium and vitamin D supplementation on parathyroid hormone secretion
    J Y Reginster
    Bone and Cartilage Research Unit, University of Liege, Liege, Belgium
    Calcif Tissue Int 70:78-82. 2002
    ..This might have implications in terms of protection of the skeleton against secondary hyperparathyroidism and increased bone resorption and turnover in elderly subjects...
  53. ncbi Secular increase in the incidence of hip fractures in Belgium between 1984 and 1996: need for a concerted public health strategy
    J Y Reginster
    School of Public Health, University of Liege, Belgium
    Bull World Health Organ 79:942-6. 2001
    ..To determine the incidence of hip fractures (at the proximal end of the femur) in Belgium from 1984 to 1996...
  54. ncbi Intermittent cyclic tiludronate in the treatment of osteoporosis
    J Y Reginster
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Department of Epidemiology and Public Health, University of Liege, Liege, Belgium
    Osteoporos Int 12:169-77. 2001
    ..Thus, tiludronate, administered at these doses in a cyclic intermittent regimen, cannot be considered an appropriate treatment of postmenopausal osteoporosis, notwithstanding a high safety profile...
  55. ncbi Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial
    J Y Reginster
    Bone and Cartilage Metabolism Research Unit WHO Collaborating Center for Public Aspects of Osteoarticular Disorders, University of Liege, Belgium
    Lancet 357:251-6. 2001
    ..Treatment of osteoarthritis is usually limited to short-term symptom control. We assessed the effects of the specific drug glucosamine sulphate on the long-term progression of osteoarthritis joint structure changes and symptoms...
  56. ncbi Evidence of nutriceutical effectiveness in the treatment of osteoarthritis
    J Y Reginster
    Bone and Cartilage Metabolism Research Unit, CHU Centre Ville, Policliniques L Brull, Quai Godefroid Kurth 45 9 ème étage, 4020 Liege, Liege, Belgium
    Curr Rheumatol Rep 2:472-7. 2000
    ..An important issue is that all the conclusive studies with such chemical entities resulted from the use of prescription medicines, and not over-the-counter pills or food supplements...
  57. ncbi Direct costs of hip fractures in patients over 60 years of age in Belgium
    J Y Reginster
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Liege, Belgium
    Pharmacoeconomics 15:507-14. 1999
    ..The goal of this paper is to estimate the direct medical expenditures associated with hip fractures in Belgium in 1996...
  58. ncbi Prevention of postmenopausal osteoporosis with pharmacological therapy: practice and possibilities
    J Y Reginster
    Unit d Exploration du Metabolisme de l Os et due Cartilage, CHU Centre Ville, Liege, Belgium
    J Intern Med 255:615-28. 2004
    ..It concludes that it is crucial for PMO prevention to start before disease onset and that, in the light of recent evidence, the existing guidelines need updating if they are to continue to be relevant...
  59. ncbi Relationship between bone mineral density changes and fracture risk reduction in patients treated with strontium ranelate
    Olivier Bruyere
    World Health Organization Collaborating Center for Public Health Aspect of Osteoarticular Disorders, University of Liege, B 4000 Liege, Belgium
    J Clin Endocrinol Metab 92:3076-81. 2007
    ..Our objective was to analyze the relationship between bone mineral density (BMD) changes and fracture incidence during 3-yr treatment with strontium ranelate...
  60. ncbi Do utility values and willingness to pay suitably reflect health outcome in hip and knee osteoarthritis? A comparative analysis with the WOMAC Index
    Olivier Ethgen
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, University of Liège CHU Sart Tilman, Avenue de l Hopital, bâtiment B23, 4020 Liege, Belgium
    J Rheumatol 30:2452-9. 2003
    ....
  61. ncbi Primary prevention of osteoporosis: mass screening scenario or prescreening with questionnaires? An economic perspective
    Florent Richy
    University of Liege, Faculty of Science, Department of Public Health, Epidemiology and Health Economics, CHU B23 Sart Tilman B 4000, Belgium
    J Bone Miner Res 19:1955-60. 2004
    ..Our results show that certain prescreening strategies are more efficient than DXA-based approaches. These results are of considerable value for health policy decision-makers and the scientific community...
  62. ncbi Cost-effectiveness of osteoporosis screening followed by treatment: the impact of medication adherence
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Liege, Belgium
    Value Health 13:394-401. 2010
    ..To estimate the impact of medication adherence on the cost-effectiveness of mass-screening by bone densitometry followed by alendronate therapy for women diagnosed with osteoporosis...
  63. ncbi Evaluation of symptomatic slow-acting drugs in osteoarthritis using the GRADE system
    Olivier Bruyere
    WHO Collaborating Center for the Public Health Aspect of Musculoskeletal Disorders, University of Liege, Belgium
    BMC Musculoskelet Disord 9:165. 2008
    ..Symptomatic slow-acting drugs (SYSADOA) have been largely studied over the last decade. The objective of this study is to prepare a document providing recommendations for the use of SYSADOA in osteoarthritis (OA)...
  64. ncbi Interest of biochemical markers of bone turnover for long-term prediction of new vertebral fracture in postmenopausal osteoporotic women
    Olivier Bruyere
    WHO Collaborating Center for Public Health Aspect of Osteoarticular Disorders, Liege, Belgium
    Maturitas 44:259-65. 2003
    ..CONCLUSION: We conclude that two sequential measurements of BGP and U-CTX performed at 3-months intervals could be of interest to identify postmenopausal osteoporotic women with the highest risk to present new vertebral deformities...
  65. ncbi Cost-effectiveness of strontium ranelate for the prevention and treatment of osteoporosis
    Mickael Hiligsmann
    Pharmacoeconomics Unit Research, HEC School of Management, University of Liege, Avenue de l hôpital 3, Bat B23, 4000 Liege, Belgium
    Expert Rev Pharmacoecon Outcomes Res 10:359-66. 2010
    ..Further analyses are required to assess the effectiveness and adherence to strontium ranelate in real-life settings, as well as to evaluate the cost-effectiveness of strontium ranelate in other countries and in populations of men...
  66. ncbi Potential clinical and economic impact of nonadherence with osteoporosis medications
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Calcif Tissue Int 86:202-10. 2010
    ..Adherence therefore remains an important challenge for health-care professionals treating osteoporosis...
  67. ncbi Direct and indirect costs attributable to osteoarthritis in active subjects
    Véronique Rabenda
    Deaprtment of Public Health, Epidemiology and Health Economics, Unviersity of Liège, 4000 Liege, Belgium
    J Rheumatol 33:1152-8. 2006
    ..To estimate the direct and indirect costs of osteoarthritis (OA) in an active population, and to identify factors significantly influencing these expenditures...
  68. ncbi Loss of hip bone mineral density over time is associated with spine and hip fracture incidence in osteoporotic postmenopausal women
    Olivier Bruyere
    Department of Public Health, Epidemiology and Health Economics, University of Liege, CHU Sart Tilman, Bat B23, 4000, Liege, Belgium
    Eur J Epidemiol 24:707-12. 2009
    ..However, spine BMD changes do not influence vertebral fracture incidence...
  69. ncbi Vitamin D inadequacy in Belgian postmenopausal osteoporotic women
    Audrey Neuprez
    Department of Epidemiology, Public Health and Health Economics, University of Liege, 4020 Liege, Belgium
    BMC Public Health 7:64. 2007
    ..Opinions with regard to the definition of vitamin D deficiency and adequate vitamin D status vary widely and there are no clear international agreements on what constitute adequate concentrations of vitamin D...
  70. ncbi Effects of long-term strontium ranelate treatment on the risk of nonvertebral and vertebral fractures in postmenopausal osteoporosis: Results of a five-year, randomized, placebo-controlled trial
    Jean Yves Reginster
    University of Liege, Liege, Belgium
    Arthritis Rheum 58:1687-95. 2008
    ..This study was undertaken to assess the effect of strontium ranelate on nonvertebral and vertebral fractures in postmenopausal women with osteoporosis in a 5-year, double-blind, placebo-controlled trial...
  71. ncbi The clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients
    Mickael Hiligsmann
    HEC School of Management, Department of Economics, University of Liege, Boulevard du Rectorat 7, Liege 1, Belgium
    Health Policy 96:170-7. 2010
    ..This study aims to estimate the clinical and economic burden of non-adherence with oral bisphosphonates in osteoporotic patients and the potential cost-effectiveness of adherence-enhancing interventions...
  72. ncbi Interest of the androgen deficiency in aging males (ADAM) questionnaire for the identification of hypogonadism in elderly community-dwelling male volunteers
    Annalisa Tancredi
    WHO Collaborating Center for Public Health Aspect of Osteoarticular Disorders, Liege, Belgium
    Eur J Endocrinol 151:355-60. 2004
    ....
  73. ncbi Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate
    Florent Richy
    Department of Public Health, Faculty of Medicine, University of Liege, Epidemiology and Health Economics, WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Liege, Belgium
    Osteoporos Int 15:301-10. 2004
    ..Their efficacy in reducing the number of fractures in patients exposed to CS remains to be determined...
  74. ncbi Vitamin D inadequacy in French osteoporotic and osteopenic women
    Caroline De Cock
    Département des Sciences de la Santé Publique, épidémiologie et économie de la santé, Universite de Liege, 4000 Liege, Belgium
    Joint Bone Spine 75:567-72. 2008
    ..The objective of this study was to evaluate the vitamin D status of postmenopausal women in France...
  75. ncbi Developments in the pharmacotherapeutic management of osteoporosis
    Pierre Close
    Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, ,
    Expert Opin Pharmacother 7:1603-15. 2006
    ....
  76. ncbi Combination/sequential therapy in osteoporosis
    Marie-Paul Lecart
    Bone and Cartilage Metabolism Research Unit, CHU Centre-Ville, Policliniques L. BRULL, Quai Godefroid Kurth 45 (9th floor, 4020 Liege, , Belgium
    Curr Osteoporos Rep 2:123-30. 2004
    ..Long-term clinical studies, using fractures as an endpoint should be initiated to better understand the clinical and pharmaco-economic interest of combination therapies in the management of osteoporosis...
  77. ncbi Osteoporosis prevalence in men varies by the normative reference
    Florent Richy
    Faculty of Medicine, Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
    J Clin Densitom 7:127-33. 2004
    ..5%) based on Hologic female norms and highest (35.8%) based on local female norms. Interpretation of prevalence data should include an assessment of how normative standards influence reporting of the population at high risk of fracture...
  78. ncbi Strontium ranelate normalizes bone mineral density in osteopenic patients
    Olivier Malaise
    WHO Collaborating Center for Public Health Aspect of Osteoarticular Disorders, University of Liege, Liege, Belgium
    Aging Clin Exp Res 19:330-3. 2007
    ..To assess the capacity of strontium ranelate to restore normal bone mineral density (WHO definition: T-score >or=-1) in post-menopausal osteopenic women (T-score between -1 and -2.5) at baseline...
  79. ncbi Evaluation of proposals of Belgian Social Security Institute for reimbursement of bone densitometry tests. Toward a cost-effective strategy for osteoporosis screening?
    Wafa Ben Sedrine
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Department of Epidemiology and Public Health, University of Liege, Liege, Belgium
    Aging Clin Exp Res 16:413-9. 2004
    ..The aim of this paper was to evaluate the diagnostic accuracy of the proposed criteria for identifying osteoporosis, and to gauge how useful they are for more rational application of densitometry tests...
  80. ncbi The effect of health related quality of life on reported use of health care resources in patients with osteoarthritis and rheumatoid arthritis: a longitudinal analysis
    Olivier Ethgen
    Department of Public Health and Epidemiology, University of Liege, Belgium
    J Rheumatol 29:1147-55. 2002
    ..Such an approach may lead to a more efficient allocation of resources by providing useful information to health care providers and health care decision makers...
  81. ncbi Age- and sex-stratified prevalence of physical disabilities and handicap in the general population
    Olivier Ethgen
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, , Belgium
    Aging Clin Exp Res 16:389-97. 2004
    ..While elderly individuals consistently report higher degrees of disability and handicap, attention should also be paid to younger age groups. Disability calls for wide, coherent and relevant medical as well as social responses...
  82. ncbi Cost-effectiveness of strontium ranelate versus risedronate in the treatment of postmenopausal osteoporotic women aged over 75 years
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Boulevard du Rectorat 7, Bât B31, 4000 Liege, Belgium
    Bone 46:440-6. 2010
    ..To estimate the cost-effectiveness of strontium ranelate in the treatment of postmenopausal osteoporotic women aged over 75 years...
  83. ncbi Lifetime absolute risk of hip and other osteoporotic fracture in Belgian women
    Mickael Hiligsmann
    Department of Economics, University of Liege, Liege, Belgium
    Bone 43:991-4. 2008
    ..To estimate the lifetime absolute risks of hip and other osteoporotic fracture in Belgian women aged 60 years and to examine the effect of changes in baseline population fracture risk and changes in life expectancy...
  84. ncbi Low incidence of anti-osteoporosis treatment after hip fracture
    Véronique Rabenda
    Department of Public Health, Epidemiology and Health Economics, 3, Avenue de l Hôpital Bat B23, Liege, Belgium
    J Bone Joint Surg Am 90:2142-8. 2008
    ....
  85. ncbi Vitamin D status and response to antiosteoporotic therapy
    Olivier Bruyere
    University of Liege, Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, Bat B23, 4000 Liege, Belgium
    Womens Health (Lond Engl) 4:445-7. 2008
    ..Moreover, the adjusted odds ratio for incident fractures in vitamin D-deficient as compared with vitamin D-repleted women was 1.77 (95% CI: 1.20-2.59; p = 0.004)...
  86. ncbi Highest prevalence of vitamin D inadequacy in institutionalized women compared with noninstitutionalized women: a case-control study
    Olivier Bruyere
    University of Liege, Department of Public Health, Epidemiology and Health Economics, CHU Sart Tilman, Bat B23, 4000 Liege, Belgium
    Womens Health (Lond Engl) 5:49-54. 2009
    ..We believe that a greater awareness of the importance of vitamin D inadequacy is needed in order to address this public health problem...
  87. ncbi Poor adherence to oral bisphosphonate treatment and its consequences: a review of the evidence
    Véronique Rabenda
    University of Liege, Department of Public Health, Epidemiology and Health Economics, Liege, Belgium
    Expert Opin Pharmacother 10:2303-15. 2009
    ..There is an urgent need to implement strategies and to encourage physicians to take measures that increase patients' awareness of the need to use osteoporosis medications as directed in order to benefit from them fully...
  88. ncbi D-hormone analog alfacalcidol: an update on its role in post-menopausal osteoporosis and rheumatoid arthritis management
    Florent Richy
    Public Health, Epidemiology and Health Economics Unit, Faculty of Medicine, University of Liege, Sart Tilman, Belgium
    Aging Clin Exp Res 17:133-42. 2005
    ..The main results of this review show that alfacalcidol may have a wider range of therapeutic applicability, beyond simply restricting it to patients in hemodialysis or peritoneal dialysis with high serum levels of intact PTH...
  89. ncbi Health-related quality of life in total hip and total knee arthroplasty. A qualitative and systematic review of the literature
    Olivier Ethgen
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Diseases, Department of Public Health, Epidemiology, and Health Economics, University of Liege, Belgium, Liege, Belgium
    J Bone Joint Surg Am 86:963-74. 2004
    ..The objective of this study was to review the literature regarding the outcomes of total hip and knee arthroplasties as evaluated by health-related quality-of-life instruments...
  90. ncbi Potential cost-effectiveness of denosumab for the treatment of postmenopausal osteoporotic women
    Mickael Hiligsmann
    HEC ULg Management School, University of Liege, Liege, Belgium
    Bone 47:34-40. 2010
    ..5 or prevalent vertebral fracture, aged 60 years and above. Additional data are needed on the relative cost-effectiveness compared with other anti-osteoporotic agents and on the long-term safety of denosumab...
  91. ncbi Development and validation of the ORACLE score to predict risk of osteoporosis
    Florent Richy
    Department of Public Health, Epidemiology and Health Economics, Universite de Liege, Liege, Belgium
    Mayo Clin Proc 79:1402-8. 2004
    ..To develop and validate a composite index, the Osteoporosis Risk Assessment by Composite Linear Estimate (ORACLE), that includes risk factors and ultrasonometric outcomes to screen for osteoporosis...
  92. ncbi Low dietary calcium in European postmenopausal osteoporotic women
    Olivier Bruyere
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders and Department of Public Health, Epidemiology and Health Economics, University of Liege, Liege, Belgium
    Public Health Nutr 12:111-4. 2009
    ..The WHO recommends a daily Ca intake for postmenopausal women of 1300 mg. The objective of the present study was to assess the dietary Ca intake in European postmenopausal osteoporotic women...
  93. ncbi No major month to month variation in free testosterone levels in aging males. Minor impact on the biological diagnosis of 'andropause'
    Annalisa Tancredi
    WHO Collaborating Center for Public Health Aspect of Osteoarticular Disorders, Liege, Belgium
    Psychoneuroendocrinology 30:638-46. 2005
    ..While the impact of age on circulating testosterone levels (total, bioavailable and free) has been strongly documented, the existence of seasonal variations in testosterone levels remains debated...
  94. ncbi Controlled whole body vibration to decrease fall risk and improve health-related quality of life of nursing home residents
    Olivier Bruyere
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Liege, Belgium
    Arch Phys Med Rehabil 86:303-7. 2005
    ..To investigate the effects of whole body vibration in the elderly...
  95. ncbi Inhaled corticosteroids effects on bone in asthmatic and COPD patients: a quantitative systematic review
    Florent Richy
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Liege, Belgium
    Osteoporos Int 14:179-90. 2003
    ..These findings could have practical implication in the long-term management of asthmatic and COPD patients...
  96. ncbi Glucosamine and chondroitin sulfate as therapeutic agents for knee and hip osteoarthritis
    Olivier Bruyere
    WHO Collaborating Center for Public Health Aspect of Osteoarticular Disorders, University of Liege, Liege, Belgium
    Drugs Aging 24:573-80. 2007
    ..With respect to the structure-modifying effect, there is compelling evidence that glucosamine sulfate and chondroitin sulfate may interfere with progression of OA...
  97. ncbi Analysis of the discriminant ability of shorter versions of the French ADAM questionnaire
    Annalisa Tancredi
    WHO Collaborating Centre for Public Health Aspect of Osteoarticular Disorders, Liege, Belgium
    Aging Male 10:159-64. 2007
    ..To investigate whether shorter versions of the ADAM test, a screening questionnaire for andropause, provide better diagnostic value than the original tool...
  98. ncbi The high prevalence of inadequate serum vitamin D levels and implications for bone health
    Jean Yves Reginster
    Department of Epidemiology, Public Health and Health Economics, University of Liege, Belgium
    Curr Med Res Opin 21:579-86. 2005
    ..Supplementation is the most effective means of correcting poor vitamin D nutrition. However, few patients with osteoporosis currently take sufficient vitamin D supplements...
  99. ncbi Utility values associated with osteoporotic fracture: a systematic review of the literature
    Mickael Hiligsmann
    Department of Epidemiology, Public Health, and Health Economics, University of Liege, Avenue de l Hopital, Bat B23, 4000 Liege, Belgium
    Calcif Tissue Int 82:288-92. 2008
    ..Although we tried to determine the best available values, these values do not preclude the need for country-specific studies. Finally, we also make recommendations regarding the design and methodology for such studies...
  100. ncbi Prevalence and impact of osteoarthritis and osteoporosis on health-related quality of life among active subjects
    Véronique Rabenda
    WHO Collaborating Center for Public Health Aspects of Osteoarticular Disorders, Department of Public Health, Epidemiology and Health Economics, University of Liege, 4000 Liege, Belgium
    Aging Clin Exp Res 19:55-60. 2007
    ..To assess the prevalence and impact of osteoarthritis (OA) and osteoporosis (OP) on health-related quality of life (HRQOL) among active subjects employed in the public workforce in Belgium...
  101. ncbi Cost effectiveness of denosumab compared with oral bisphosphonates in the treatment of post-menopausal osteoporotic women in Belgium
    Mickael Hiligsmann
    Pharmacoeconomics Research Unit, University of Liege, Belgium
    Pharmacoeconomics 29:895-911. 2011
    ..However, further studies would be required to evaluate the long-term safety and adherence of denosumab in real-world clinical practice as well as head-to-head effectiveness compared with oral bisphosphonates...